Reasons Behind Essential Drug Shortages Revealed by Ativan Supply Disruptions

71% of Pediatric Hospitals Report "Stock Will Run Out Before July"

Budesonide and Fever-Reducing Syrups Also Frequently in Short Supply

"Urgent Need for Pri

Essential injectable drugs used in pediatric emergency rooms and children's hospitals are facing repeated supply disruptions, triggering an emergency situation in the medical field. Although the government has sought alternative pharmaceutical companies to secure urgent supplies, on-site inventories have already been depleted, raising concerns that a "medical crisis" could erupt this summer.


[Why&Next] Injectable Drugs Cheaper Than "Mychew"... Essential Pediatric Medicines That Lose Money the More They Are Made View original image

According to the medical community on May 18, the supply of Ativan (active ingredient: lorazepam), an essential first-line treatment for pediatric seizure patients, was recently halted. In addition, production of Cortisol Injection (hydrocortisone sodium succinate), a blood pressure control injectable for newborns, is scheduled to stop from July.


For Ativan, the Ministry of Food and Drug Safety is pursuing a plan for Samjin Pharmaceutical to produce the drug as a substitute for the existing manufacturer and supplier, Ildong Pharmaceutical. As for Cortisol Injection, supply is expected to resume around November to December. However, for both drugs, stocks at medical sites are running out, and there is expected to be a gap between the depletion of existing supplies and the arrival of new products.


An emergency survey conducted by the Korean Association of Pediatric Hospitals among pediatric hospitals nationwide found that 34% (12 out of 35) of respondent hospitals have already completely run out of Ativan injection stock and are unable to treat emergency patients. In addition, 37% (13 hospitals) responded that "stocks will be depleted within 1-2 months," meaning that 71% of all hospitals are certain to experience paralysis in patient care due to the depletion of Ativan stocks before summer arrives. Among these hospitals, 23% reported that "over the past six months, they have had to transfer patients to other hospitals due to unstable Ativan supply," and 43% of medical staff said, "They are under extreme stress due to concerns about side effects from using alternative drugs."


Recurring Shortages in Pediatric Care Settings


The medical community points out that this situation was in fact predictable. Lee Hongjun, director of Gimpo Ai Jeil Hospital, stated, "The price for a single ampoule of Ativan injection is a mere 782 won, which is even less than the price of a pack of Mychew, a snack popular among children," and diagnosed, "Low profitability and excessive regulation are combining to accelerate the disappearance of essential medicines—considered public goods—from the market." Production costs such as raw materials and labor have been rising rapidly every year, but drug prices remain frozen, creating a structure in which pharmaceutical companies lose money the more they produce.


For Cortisol Injection, the maximum price is reportedly only 820 won per 100 mg vial, and just 410 won for the typical neonatal dose (50 mg). Due to this low pricing structure and the resulting production burden, the manufacturer has halted its production line, citing equipment maintenance as the reason.


[Why&Next] Injectable Drugs Cheaper Than "Mychew"... Essential Pediatric Medicines That Lose Money the More They Are Made View original image

Budesonide inhalation, a respiratory treatment essential for relieving airway obstruction in children with croup (laryngotracheobronchitis), also faces continuous risk of stockouts due to supply shortages. During outbreaks of colds or influenza, fever reducers such as acetaminophen syrup are often in short supply, triggering stockpiling competition among pharmacies and hospitals.


Han Donggyun, director of Mirae Children's Hospital in Nam-gu, Gwangju, lamented, "Due to the impact of low birth rates and other factors, the usage of essential pediatric medications has plummeted, making manufacturers reluctant to produce them from a supplier's perspective." He added, "As a result, in urgent cases, it is becoming common to divide adult medications into smaller doses for pediatric patients because the necessary drugs are simply unavailable."


Specialists especially criticized the health authorities' explanation that the existence of substitute drugs means there is no major problem, calling it "an armchair theory that ignores clinical realities and a dangerous idea that puts children's lives at risk." Ativan is the only drug that can act within 5 to 10 minutes to protect the brain during the critical "golden hour," and it is considered the safest and irreplaceable first-line option for children due to its lower respiratory irritation compared to other medications.


Cortisol Injection is the only drug that can be administered when extremely premature infants or critically ill pediatric patients in shock do not respond to fluids or vasopressors. While alternative drugs are available for adults, the medical community agrees that there are no substitutes for newborns.



Choi Yongjae, president of the Korean Association of Pediatric Hospitals (director of Tuntun Children's Hospital in Uijeongbu, Gyeonggi Province), emphasized, "For these ultra-low-priced essential medications, a separate system in which the state reimburses production and management costs must be established. In addition, an 'automatic trigger system' should be implemented so that, when a pharmaceutical company's supply suspension report is received, the relevant authorities automatically respond in concert."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing